Specific CAR T-cell subgroup could make lower-dose cancer therapy more effective

Immunotherapies strengthen the body's own anticancer defenses in a highly targeted manner. In therapies using so-called CAR T cells (chimeric antigen receptor T cells), a patient's immune cells are genetically engineered and directed against individual cancer cells. Until now, it has remained unclear why even very low CAR T-cell doses are effective in some patients while others do not benefit from the treatment.

Read it at Medical Xpress ↗

← Front page